SCHEMBL6445773

SCHEMBL6445773

Cc1ccc(C(=O)Nc2nnc(-c3cc(Cl)cc(Cl)c3O)s2)cc1Br

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 3/20 0.46
RAB9A P51151 3/20 0.46
SMN1; SMN2 Q16637 3/20 0.46
KDM4E B2RXH2 2/20 0.46
MEN1 O00255 1/20 0.46
HPGD P15428 1/20 0.46
PPARG P37231 1/20 0.46
KMT2A Q03164 1/20 0.46
NCOA2 Q15596 1/20 0.46
NCOA1 Q15788 1/20 0.46
HSD17B10 Q99714 1/20 0.46
PTGER3 P43115 11/20 0.45
MAPT P10636 1/20 0.43
ALDH1A1 P00352 1/20 0.42
MAPK1 P28482 1/20 0.42
TAS1R3 Q7RTX0 1/20 0.42
TAS1R1 Q7RTX1 1/20 0.42
TAS1R2 Q8TE23 1/20 0.42
CA1 P00915 1/20 0.41
CA2 P00918 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6449245 0.92 NPC1 (0.46) NPC1RAB9ASMN1; SMN2KDM4EMEN1
SCHEMBL6448551 0.88 KDM4E (0.48) NPC1RAB9ASMN1; SMN2KDM4EMEN1
SCHEMBL6449394 0.88 TAS1R3 (0.49) NPC1RAB9ASMN1; SMN2KDM4EMEN1
SCHEMBL6447124 0.87 PTGER3 (0.52) NPC1RAB9ASMN1; SMN2KDM4EMEN1
SCHEMBL6445925 0.86 MAPT (0.53) NPC1RAB9ASMN1; SMN2KDM4EMEN1
SCHEMBL6445716 0.85 GLB1 (0.49) NPC1RAB9AKDM4EMEN1KMT2A
SCHEMBL6446020 0.84 KMT2A (0.48) NPC1RAB9ASMN1; SMN2KDM4EMEN1
SCHEMBL6448535 0.84 MEN1 (0.53) NPC1RAB9ASMN1; SMN2MEN1HPGD
SCHEMBL6445418 0.83 MEN1 (0.51) NPC1RAB9ASMN1; SMN2KDM4EMEN1
SCHEMBL6444242 0.83 RAB9A (0.52) NPC1RAB9ASMN1; SMN2KDM4EMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050143384-A1 Amide thiadiazole inhibitors of plasminogen activator inhibitor-1 BRISTOL-MYERS SQUIBB COMPANY 2005-06-30 US claimed
US-20050143384-A1 Amide thiadiazole inhibitors of plasminogen activator inhibitor-1 BRISTOL-MYERS SQUIBB COMPANY 2005-06-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050143384-A1 Amide thiadiazole inhibitors of plasminogen activator inhibitor-1 SERPINE1, SERPINC1, SERPINB1 NPC1 1404/4885RAB9A 1792/4885SMN1; SMN2 2751/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.